Document:

EX-10.4

 Exhibit 10.4 
 EMPLOYMENT AGREEMENT 
 This Employment Agreement (this “Agreement”) is entered
into on February 29, 2012, between DDR Corp., an Ohio corporation (“DDR”), and Christa A. Vesy (“Executive”). 

Executive is now serving DDR as its Senior Vice President & Chief Accounting Officer. Executive and DDR are currently party to an Employment
Agreement, dated April 12, 2011, which will expire on February 28, 2012. DDR and Executive desire to enter into this Agreement effective on February 29, 2012 (the “Effective Date”) to reflect the terms pursuant to which
Executive will continue to serve DDR. Certain capitalized terms used in this Agreement have the meanings ascribed to them in Section 21 of this Agreement. 
 DDR and Executive agree, effective as of the Effective Date, as follows: 
 1. Employment,
Term. DDR engages and employs Executive to render services in the administration and operation of its affairs as its Executive Vice President & Chief Accounting Officer, reporting directly to DDR’s Chief Financial Officer (the
“CFO”), all in accordance with the terms and conditions of this Agreement, for a term beginning on the Effective Date and expiring on February 28, 2013. The period of time from the Effective Date until February 28, 2013 is
sometimes referred to herein as the “Contract Period.” 
 2. Full-Time Services. Throughout the Contract Period while Executive
is employed by DDR, Executive will devote all of Executive’s business time and efforts to the service of DDR, except for (a) usual vacation periods and reasonable periods of illness, (b) reasonable periods of time devoted to
Executive’s personal financial affairs, and (c) services as a director or trustee of other corporations or organizations, either for profit or not for profit, that are not in competition with DDR; provided, that in no event shall
Executive devote less than 90% of Executive’s business time and efforts to the service of DDR. 
 3. Compensation. For
all services to be rendered by Executive to DDR under this Agreement during the Contract Period while Executive is employed by DDR, including services as Executive Vice President & Chief Accounting Officer, and any other services specified
by the CFO, DDR will pay and provide to Executive the compensation and benefits specified in this Section 3. 

3.1 Base Salary. From and after the Effective Date and through the Contract Period while Executive is employed by DDR, DDR will
pay Executive base salary (the “Base Salary”), in equal monthly or more frequent installments, at the rate of not less than Two Hundred Fifty-Five Thousand Dollars ($255,000) per year, subject to such increases as approved by DDR.

 3.2 Annual Cash Bonus. In addition to Base Salary, if Executive achieves the factors and criteria for annual bonus
compensation hereinafter described for any calendar year (beginning with 2012) during the Contract Period while Executive is employed by DDR, then DDR shall pay an annual bonus to Executive, in cash (an “Annual Cash Bonus”), for such
calendar year not later than March 15 of the immediately subsequent calendar year, determined and calculated in accordance with the percentages set forth on Exhibit A attached hereto. DDR’s award of an Annual Cash Bonus to Executive
shall be determined based on the factors and criteria that may be established from time to time for the calculation of the Annual Cash Bonus by DDR; provided, that for 2012, the Annual Cash Bonus for Executive will be determined in accordance
with the performance metrics and their relative weighting set forth on Exhibit A attached hereto. For 2013, if Executive 

 
is then employed by DDR, DDR will provide Executive with written notice of the performance metrics and their relative weighting to be used in, and any specific threshold, target and maximum
performance targets applicable to, the determination of the Annual Cash Bonus for Executive for such calendar year not later than March 15th of such year. There is no guaranteed Annual Cash Bonus under this Agreement, and for each applicable
year, Executive’s Annual Cash Bonus could be as low as zero or as high as the maximum percentage set forth on Exhibit A attached hereto. 
 3.3 Annual Equity Bonus. If Executive achieves the factors and criteria for an Annual Cash Bonus, as described in Section 3.2, for any calendar year (beginning with 2012) during the Contract
Period while Executive is employed by DDR, then DDR shall pay an annual bonus to Executive, in the form of a time-based vesting equity award (an “Annual Equity Bonus”), for such calendar year not later than March 15 of the immediately
subsequent calendar year, determined and calculated in accordance with the percentages set forth on Exhibit A attached hereto. DDR’s award of an Annual Equity Bonus to Executive shall be determined based on the factors and criteria that may be
established from time to time for the calculation of the Annual Equity Bonus by DDR; provided, that for 2012, the Annual Equity Bonus for Executive will be determined in accordance with the performance metrics and their relative weighting set forth
on Exhibit A attached hereto. For 2013, if Executive is then employed by DDR, DDR will provide Executive with written notice of the performance metrics and their relative weighting to be used in, and any specific threshold, target and maximum
performance targets applicable to, the determination of the Annual Equity Bonus for Executive for such calendar year not later than March 15th of such year. There is no guaranteed Annual Equity Bonus under this Agreement, and for each
applicable year, Executive’s Annual Equity Bonus could be as low as zero or as high as the maximum percentage set forth on Exhibit A attached hereto. The Annual Equity Bonus shall be on the terms and subject to such conditions as are specified
for the particular Company plans or programs pursuant to which the Annual Equity Bonus is granted. 
 3.4 Equity Awards.
During the Contract Period while Executive is employed by DDR, Executive shall be entitled to participate in any equity or other employee benefit plan that is generally available to senior executive officers, as distinguished from general
management, of DDR, including, without limitation, any long-term incentive compensation plans or similar programs. Executive’s participation in and benefits under any such plans or programs shall be on the terms and subject to such conditions
as are specified for the particular Company plans or programs. 
 3.5 Taxes. Executive shall be solely responsible for
taxes imposed on Executive by reason of any compensation and benefits provided under this Agreement, and all such compensation and benefits shall be subject to applicable withholding taxes. 
 4. Benefits. 
 4.1 Retirement and Other Benefit Plans Generally.
Throughout the Contract Period while Executive is employed by DDR, Executive will be entitled to participate in all retirement and other benefit plans maintained by DDR that are generally available to its employees and with respect to which
Executive is eligible pursuant to the terms of the underlying plan or plans, including, without limitation, the DDR 401(k) plan for its employees and any DDR deferred compensation program. 

  
 2 

 4.2 Insurance, Generally. Throughout the Contract Period while Executive is employed
by DDR, DDR will provide an enrollment opportunity to Executive and Executive’s eligible dependents for health, dental and vision insurance coverage and any other benefits maintained by DDR from time to time, if any, during the Contract Period
that are generally available to its employees and with respect to which Executive is eligible pursuant to the terms of the underlying plan or plans. 
 4.3 Paid Time Off. Executive will be entitled to such periods of paid time off during the Contract Period while Executive is employed by DDR as may be determined by the CFO in his or her reasonable
and good faith discretion (but in any event not less than 20 days per year or such longer period as may be provided from time to time under any DDR paid time off policy for executive officers). 

5. Expense Reimbursement. DDR will reimburse Executive during the Contract Period while Executive is employed by DDR for travel, entertainment,
and other expenses reasonably and necessarily incurred by Executive in connection with DDR’s business. Executive will provide such documentation with respect to expenses to be reimbursed as DDR may reasonably request. 

6. Termination. 
 6.1
Death or Disability. Executive’s employment under this Agreement will terminate immediately upon Executive’s death. DDR may terminate Executive’s employment under this Agreement immediately upon giving notice of termination if
Executive is Totally Disabled (as that term is defined in Section 9.1 below) for an aggregate of 120 days in any consecutive 12 calendar months or for 90 consecutive days. 

6.2 For Cause by DDR. 
 (a) During the Contract Period while Executive is employed by DDR, DDR may terminate Executive’s employment under this Agreement for “Cause” at any time upon the occurrence of any of the
following circumstances: 
 (i) (A) Executive commits a fraud or a felony or an act that is not or a series of acts that are not
taken in good faith and (B) the commission of such fraud, felony or act or series of acts results in material injury to the business reputation of DDR. 
 (ii) Executive commits an act or series of repeated acts of dishonesty that are materially inimical to the best interests of DDR. 
 (iii) Other than as a result of disability, Executive consistently fails to perform Executive’s duties and responsibilities as specified in Sections 1 and 2 above and the
failure continues for 15 days after DDR has advised Executive in writing of that failure. 
 (iv) Executive has materially
breached any provision of this Agreement (other than Section 1 or 2 above, as to any breach of which Section 6.2(a)(iii) would apply) and the breach has not been cured in all substantial respects
within 30 days after DDR has advised Executive in writing of the nature of the breach. 

  
 3 

 (b) The termination of Executive’s employment under this Agreement shall not be deemed
to be for Cause pursuant to this Section 6.2 unless and until there shall have been delivered to Executive reasonable notice that Executive is guilty of the conduct described in Sections 6.2(a)(i),
(ii), (iii) or (iv) above, and specifying the particulars thereof in detail. 
 6.3 For Good Reason by Executive. During the Contract Period while Executive is employed by DDR, Executive may terminate Executive’s employment under this Agreement for “Good Reason”
if any of the following circumstances occur: 
 (a) DDR materially changes Executive’s duties and responsibilities from
those set forth in Section 1 above and the change has not been rescinded to Executive’s satisfaction within 15 days after Executive has advised DDR in writing of dissatisfaction with the change. 

(b) DDR changes Executive’s place of employment or its principal executive offices to a location that is more than 50 miles from the
geographical center of Cleveland, Ohio. 
 (c) DDR materially breaches any of its obligations under this Agreement (other than
its obligations under Section 1 above, as to any breach of which Section 6.3(a) would apply) and the breach is not cured in all material respects within 30 days after Executive has advised DDR in writing of the
breach. 
 6.4 Without Cause by DDR. During the Contract Period while Executive is employed by DDR, DDR may terminate
Executive’s employment under this Agreement at any time without Cause pursuant to written notice provided to Executive not less than 90 days in advance of such termination. Any termination under this Section 6.4 will be
effective at such time during the Contract Period while Executive is employed by DDR as may be specified in that written notice. 
 6.5 Without Good Reason by Executive. During the Contract Period while Executive is employed by DDR, Executive may terminate Executive’s employment under this Agreement at any time without
Good Reason pursuant to written notice provided to DDR not less than 90 days in advance of such termination. Any termination under this Section 6.5 will be effective at such time during the Contract Period while Executive is
employed by DDR as Executive may specify in that written notice. 
 7. Payments upon Termination. 

7.1 Upon Termination For Cause or Without Good Reason. If Executive’s employment under this Agreement is terminated by DDR for
Cause or by Executive without Good Reason during the Contract Period, DDR will pay and provide to Executive the Executive’s Base Salary through the Termination Date to the extent not already paid and continuing health, dental and vision
insurance at the levels specified in Section 4.2 through the Termination Date, and, except as may otherwise be required by law, DDR will not pay or provide to Executive any further compensation or other benefits under this
Agreement. DDR will pay any Base Salary referred to in this Section 7.1 to Executive within 30 days of the Termination Date. 
 7.2 Upon Termination Without Cause or For Good Reason. If Executive’s employment under this Agreement is terminated by DDR without Cause or by Executive for Good Reason during the

  
 4 

 
Contract Period and Section 7.5 does not apply, DDR will pay and provide to Executive the amounts and benefits specified in this Section 7.2, except that DDR
will not be obligated to pay the lump sum amounts specified in Section 7.2(c) unless either (x) DDR is deemed to have waived the obligation to provide a Release as provided in Section 8.2 or
(y) Executive has timely executed a Release as contemplated by Section 8.3. The amounts and benefits specified in this Section 7.2 are as follows: 

(a) A lump sum amount equal to Executive’s Base Salary for the year through the Termination Date, to the extent not already paid.
DDR will pay this amount to Executive within 30 days of the Termination Date. 
 (b) A lump sum amount equal to
Executive’s Annual Cash Bonus earned for the calendar year immediately preceding the calendar year in which the Termination Date occurs, to the extent not already paid. DDR will pay this amount to Executive on the same date and in the same
amount that the Annual Cash Bonus for such year would have been paid if Executive’s employment had not been terminated, but in any event not later than March 15 of the calendar year in which the Termination Date occurs. 

(c) A lump sum amount equal to (i) one year of Executive’s Base Salary as of the Termination Date, plus (ii) the Annual
Cash Bonus at the target level for Executive for the year in which the Termination Date occurs. Except as otherwise provided in Section 13.2, DDR will pay the amount referred to in this Section 7.2(c)(i) to
Executive during the Seventh Month after the Termination Date (as defined in Section 13.1 below) and will pay the amount referred to in this Section 7.2(c)(ii) to Executive on the same date that the Annual Cash
Bonus for that year would have been paid if Executive’s employment had not been terminated, but in any event not later than March 15 of the calendar year following the calendar year in which Executive’s employment is terminated
pursuant to this Section 7.2. 
 (d) Provided that Executive timely elects continuation coverage under
DDR’s health and dental plan pursuant to COBRA, DDR shall pay the COBRA premiums for Executive until the first anniversary of the Termination Date. Such payments shall be taxable to the Executive. To assure compliance with Section 409A,
the timing of the provision of these benefits will be subject to Sections 13.1 and 13.3 if and to the extent either of those sections is applicable according to its terms. 

(e) Outplacement services and support, the reasonable scope and provider of which will be selected by DDR, for a period of one year
following the Termination Date; provided, that Executive must first utilize such outplacement services and support within 90 days following the Termination Date. To assure compliance with Section 409A, the timing of the provision of
these benefits will be subject to Sections 13.1 and 13.3 if and to the extent either of those sections is applicable according to its terms. 
 7.3 Upon Termination by Reason of Death. If Executive’s employment under this Agreement is terminated by reason of Executive’s death during the Contract Period, DDR will pay, or cause to
be paid, and provide, or cause to be provided, to Executive’s personal representative and Executive’s eligible dependents, as appropriate, the amounts and benefits specified in this Section 7.3, except that DDR will not
be obligated to pay the lump sum amount specified in Section 7.3(c) unless either (x) DDR is deemed to have waived the obligation to provide a 

  
 5 

 
Release as provided in Section 8.2 or (y) Executive’s personal representative has timely executed a Release as contemplated by Section 8.3. The
amounts and benefits specified in this Section 7.3 are as follows: 
 (a) A lump sum amount equal to
Executive’s Base Salary for the year through the Termination Date, to the extent not already paid. DDR will pay this amount to Executive’s personal representative within 30 days of the Termination Date. 

(b) A lump sum amount equal to Executive’s Annual Cash Bonus earned for the calendar year immediately preceding the calendar year in
which the Termination Date occurs, to the extent not already paid. DDR will pay this amount to Executive’s personal representative on the same date and in the same amount that the Annual Cash Bonus for such year would have been paid if
Executive’s employment had not been terminated, but in any event not later than March 15 of the calendar year in which the Termination Date occurs. 
 (c) A lump sum amount equal to (i) one year of Executive’s Base Salary as of the Termination Date, plus (ii) the Annual Cash Bonus at the target level for Executive for the year in which
the Termination Date occurs. Except as otherwise provided in Section 13.2, DDR will pay the amount referred to in this Section 7.3(c)(i) to Executive’s personal representative as soon as practicable
following Executive’s death, but in no event later than March 15 of the year after the year in which Executive’s death occurs (provided that neither Executive nor Executive’s estate may designate the taxable year of payment) and
will pay the amount referred to in this Section 7.3(c)(ii) to Executive on the same date that the Annual Cash Bonus for that year would have been paid if Executive’s employment had not been terminated, but in any event not
later than March 15 of the calendar year following the calendar year in which Executive’s employment is terminated. 

(d) Continuing health, dental and vision insurance coverage and benefits to Executive’s eligible dependents at the levels specified
in Section 4.2 until the first anniversary of the Termination Date. To assure compliance with Section 409A, the timing of the provision of these benefits will be subject to Sections 13.1 and 13.3
if and to the extent either of those sections is applicable according to its terms. 
 7.4 Upon Termination by Reason of
Disability. If Executive’s employment under this Agreement is terminated by DDR pursuant to Section 6.1 during the Contract Period following Executive’s disability, DDR will pay and provide to Executive and
Executive’s eligible dependents, as appropriate, the amounts and benefits specified in this Section 7.4. The amounts and benefits specified in this Section 7.4 are as follows: 

(a) A lump sum amount equal to Executive’s Base Salary for the year through the Termination Date, to the extent not already paid.
DDR will pay this amount to Executive within 30 days of the Termination Date. 
 (b) A lump sum amount equal to Executive’s
Annual Cash Bonus earned for the calendar year immediately preceding the calendar year in which the Termination Date occurs, to the extent not already paid. DDR will pay this amount to Executive on the same date and in the same amount that the
Annual Cash Bonus for such year would have been paid if 

  
 6 

 
Executive’s employment had not been terminated, but in any event not later than March 15 of the calendar year in which the Termination Date occurs. 

(c) A lump sum amount equal to (i) Executive’s Base Salary for one year as of the Termination Date, plus (ii) the Annual
Cash Bonus for Executive at the target level for the year in which the Termination Date occurs. Except as otherwise provided in Section 13.2, DDR will pay the amount referred to in this Section 7.4(c)(i) to
Executive during the Seventh Month after the Termination Date (as defined in Section 13.1 below) and will pay the amount referred to in this Section 7.4(c)(ii) to Executive on the same date that the Annual Cash
Bonus for that year would have been paid if Executive’s employment had not been terminated, but in any event not later than March 15 of the calendar year following the calendar year in which Executive’s employment is terminated by
DDR. 
 (d) Continuing health, dental and vision insurance coverage and benefits to Executive and Executive’s eligible
dependents at the levels specified in Section 4.2 until the first anniversary of the Termination Date. To assure compliance with Section 409A, the timing of the provision of these benefits will be subject to Sections
13.1 and 13.3 if and to the extent either of those sections is applicable according to its terms. 
 7.5
Upon Termination In Connection With a Change in Control. Upon the occurrence of a Triggering Event during the Contract Period while Executive is employed by DDR, DDR will pay and provide to Executive the amounts and benefits specified in this
Section 7.5, and DDR will be deemed to have waived its right to provide a Release as provided in Section 8.2, and the provision of a Release will not be a condition to Executive receiving any payment or benefit
from DDR under this Section 7.5. The amounts and benefits specified in this Section 7.5 are as follows: 
 (a) A lump sum amount equal to Executive’s Base Salary through the Termination Date, to the extent not already paid. DDR will pay this amount to Executive within 30 days of the Termination Date.

 (b) A lump sum amount equal to Executive’s Annual Cash Bonus earned for the calendar year immediately preceding the
calendar year in which the Termination Date occurs, to the extent not already paid. DDR will pay this amount to Executive on the same date and in the same amount that the Annual Cash Bonus for such year would have been paid if Executive’s
employment had not been terminated, but in any event not later than March 15 of the calendar year in which the Termination Date occurs. 
 (c) A lump sum amount equal to (i) two times Executive’s target Annual Cash Bonus for the year in which the Termination Date occurs plus (ii) two times Executive’s annual Base Salary
as of the Termination Date. Except as otherwise provided in Section 13.2, DDR will pay this amount to Executive during the Seventh Month after the Termination Date (as defined in Section 13.1 below). 

(d) Provided that Executive timely elects continuation coverage under DDR’s health and dental plan pursuant to COBRA, DDR shall pay
the COBRA premiums for the Executive until the 18-month anniversary of the Termination Date. Such payments shall be taxable to Executive. To assure compliance with Section 409A, the timing of the provision of

  
 7 

 
these benefits will be subject to Sections 13.1 and 13.3 if and to the extent either of those sections is applicable according to its terms. 

(e) Outplacement services and support, the reasonable scope and provider of which will be selected by DDR, for a period of one year
following the Termination Date; provided, that Executive must first utilize such outplacement services and support within 90 days following the Termination Date. To assure compliance with Section 409A, the timing of the provision of
these benefits will be subject to Sections 13.1 and 13.3 if and to the extent either of those sections is applicable according to its terms. 
 8. Release. This Section 8 will apply only upon termination of Executive’s employment during the Contract Period (a) by reason of Executive’s death, (b) by
DDR without Cause or (c) by Executive for Good Reason. 
 8.1 Presentation of Release by DDR. If this
Section 8 applies, DDR may present to Executive (or in the case of Executive’s death or legal incapacity, to Executive’s personal representative), not later than 21 days after the Termination Date, a form of release (a
“Release”) of all current and future claims, known or unknown, arising on or before the date on which the Release is to be executed, that Executive or Executive’s assigns have or may have against DDR or any Subsidiary, and the
directors, officers, and affiliates of any of them, in such form as may reasonably be presented by DDR together with a covering message in which DDR advises Executive (or Executive’s personal representative) that the Release is being presented
in accordance with this Section 8.1 and that a failure by Executive (or Executive’s personal representative) to execute and return the Release as contemplated by Section 8.3 would relieve DDR of the
obligation to make payments otherwise due to Executive (or to Executive’s personal representative) under one or more portions of either of Sections 7.2 or 7.3, as the case may be. 

8.2 Effect of Failure by DDR to Present Release. If DDR fails to present a Release and covering message to Executive (or
Executive’s personal representative) as contemplated by Section 8.1, DDR will be deemed to have waived the requirement that Executive (or Executive’s personal representative) execute a Release as a condition to receiving
payments under any portion of either of Sections 7.2 or 7.3, as the case may be. 
 8.3 Execution
of Release by Executive or Executive’s Personal Representative. If DDR does present a Release and covering message to Executive (or Executive’s personal representative) as contemplated by Section 8.1, Executive (or
Executive’s personal representative) will have until 50 days after the Termination Date (i.e., at least 29 days after presentation of the Release to Executive (or Executive’s personal representative) within which to deliver an
executed copy of the Release to DDR and thereby satisfy the condition to receiving payments under any portion of either of Sections 7.2 or 7.3, as the case may be, provided that Executive (or Executive’s personal
representative) does not revoke the execution of the Release during any applicable revocation period. 
 8.4 Effect of
Failure to Execute Release or of Revocation of Release. If Executive (or Executive’s personal representative) fails to deliver an executed copy of the Release to DDR within 50 days after the Termination Date or revokes the execution of the
Release during any applicable revocation period, Executive (or Executive’s personal representative) will be deemed to have waived the right to receive all payments under Sections 7.2 or 7.3, as the case may be, that
were conditioned on the Release. 

  
 8 

 9. Disability Definitions; Physical Examination. 

9.1 Definitions. For all purposes of this Agreement: 
 (a) Executive’s “Own Occupation” means the regular occupation in which Executive is engaged under this Agreement at the time Executive becomes disabled. 

(b) “Total Disability” means that, because of sickness or injury, Executive is not able to perform the material and substantial
duties of Executive’s Own Occupation. 
 (c) “Totally Disabled” means that Executive suffers from Total
Disability (and Executive will be deemed to continue to be Totally Disabled so long as Executive is not able to work in Executive’s Own Occupation even if Executive works in some other capacity). 

9.2 Physical Examination. If either DDR or Executive, at any time or from time to time after receipt of notice of Executive’s
Total Disability from the other, desires to contend that Executive is not Totally Disabled, Executive will promptly submit to a physical examination by the chief of medicine of any major accredited hospital in the Cleveland, Ohio area and, unless
that physician issues his or her written statement to the effect that, in his or her opinion, based on his or her diagnosis, Executive is capable of resuming Executive’s Own Occupation and devoting Executive’s full time and energy to
discharging the duties of Executive’s Own Occupation, Executive will be deemed to be and to continue to be Totally Disabled for all purposes of this Agreement. 
 10. No Set-Off; No Obligation to Seek Other Employment or to Otherwise Mitigate Damages; No Effect Upon Other Plans. DDR’s obligation to make the payments provided for in this
Agreement and otherwise to perform its obligations under this Agreement will not be affected by any set-off, counterclaim, recoupment, defense, or other claim whatsoever that DDR or any Subsidiary may have against Executive, except that the
prohibition on set-off, counterclaim, recoupment, defense, or other claim contained in this sentence will not apply if Executive’s employment is terminated by DDR for Cause. Executive will not be required to mitigate damages or the amount of
any payment provided for under this Agreement by seeking other employment or otherwise. The amount of any payment provided for under this Agreement will not be reduced by any compensation or benefits earned by Executive as the result of employment
by another employer or otherwise after the Termination Date. Neither the provisions of this Agreement nor the making of any payment provided for under this Agreement, nor the termination of DDR’s obligations under this Agreement, will reduce
any amounts otherwise payable, or in any way diminish Executive’s rights, under any incentive compensation plan, stock option or stock appreciation rights plan, restricted stock plan or agreement, deferred compensation, retirement, or
supplemental retirement plan, stock purchase and savings plan, disability or insurance plan, or other similar contract, plan, or arrangement of DDR or any Subsidiary, all of which will be governed by their respective terms. 

11. Payments Are in Lieu of Severance Payments. If Executive becomes entitled to receive payments under this
Agreement as a result of termination of Executive’s employment, those payments will be in lieu of any and all other claims or rights that Executive may have against DDR for severance, separation, and/or salary continuation pay upon that
termination of Executive’s employment. 
 12. Covenants and Confidential Information. Executive acknowledges
DDR’s reliance on and expectation of Executive’s continued commitment to performance of Executive’s duties and responsibilities during the Contract Period while Executive is employed by DDR and Executive assumes the obligations set
out in this Section 12 in light of that reliance and expectation on the part of DDR. 

  
 9 

 12.1 Noncompetition. During the Contract Period while Executive is employed by DDR,
and for one year after the Termination Date, Executive will not, directly or indirectly, own, manage, control, or participate in the ownership, management, or control of, or be employed or engaged by or otherwise affiliated or associated as a
consultant, independent contractor, or otherwise with, any of the four largest real estate investment trusts (excluding DDR) that focus primarily on neighborhood and community shopping centers, based on market capitalization as of the Termination
Date; provided, however, that the ownership by Executive of not more than one percent of any class of publicly traded securities of any entity will not be deemed a violation of this Section 12.1. 

12.2 Confidentiality. Throughout the Contract Period and for a period of two years thereafter, Executive will not disclose,
divulge, discuss, copy, or otherwise use or suffer to be used in any manner, in competition with, or contrary to the interests of, DDR, any confidential information relating to DDR’s operations, properties, or otherwise to its particular
business or other trade secrets of DDR, it being acknowledged by Executive that all such information regarding the business of DDR compiled or obtained by, or furnished to, Executive during Executive’s employment by or association with DDR
is confidential information and DDR’s exclusive property. The restrictions in this Section 12.2 will not apply to any information to the extent that it (a) is clearly obtainable in the public domain, (b) becomes
obtainable in the public domain, except by reason of the breach by Executive of Executive’s obligations under this Section 12.2, (c) was not acquired by Executive in connection with Executive’s employment or
affiliation with DDR, (d) was not acquired by Executive from DDR or its representatives, or (e) is required to be disclosed by rule of law or by order of a court or governmental body or agency. 

12.3 Nonsolicitation. During the Contract Period while Executive is employed by DDR, and for one year after the Termination Date,
Executive will not directly or indirectly solicit or induce or attempt to solicit or induce any employee of DDR and/or of any Subsidiary or affiliate to terminate his or her employment with DDR and/or any Subsidiary. 

12.4 Remedies. Executive acknowledges that the remedy at law for any breach by Executive of this Section 12 may
be inadequate and that the damages following from any such breach may not be readily susceptible to being measured in monetary terms. Accordingly, Executive agrees that, upon adequate proof of Executive’s violation of any legally enforceable
provision of this Section 12, DDR will be entitled to immediate injunctive relief and may obtain a temporary order restraining any threatened or further breach. Nothing in this Section 12 will be deemed to limit
DDR’s remedies at law or in equity for any breach by Executive of any of the provisions of this Section 12 that may be pursued or availed of by DDR. 
 12.5 Acknowledgement. Executive has carefully considered the nature and extent of the restrictions upon Executive and the rights and remedies conferred upon DDR under this
Section 12, and hereby acknowledges and agrees that the same are reasonable in time and territory, are designed to eliminate competition that otherwise would be unfair to DDR, do not stifle the inherent skill and experience of
Executive, would not operate as a bar to Executive’s sole means of support, are fully required to protect the legitimate interests of DDR and do not confer a benefit upon DDR disproportionate to the detriment to Executive. 

  
 10 

 13. Compliance with Section 409A. 

13.1 Six Month Delay on Certain Payments, Benefits, and Reimbursements. If Executive is a “specified employee” for
purposes of Section 409A, as determined under DDR’s policy for determining specified employees on the Termination Date, each payment, benefit, or reimbursement paid or provided under this Agreement that constitutes a “deferral of
compensation” within the meaning of Section 409A, that is to be paid or provided as a result of a “separation from service” within the meaning of Section 409A, and that would otherwise be paid or provided at any time (a
“Scheduled Time”) that is on or before the date (the “Six Month Date”) that is exactly six months after the Termination Date (other than payments, benefits, or reimbursements that are treated as separation pay under
Section 1.409A-1(b)(9)(v) of the Treasury Regulations) will not be paid or provided at the Scheduled Time but will be accumulated (together with interest at the applicable federal rate under Section 7872(f)(2)(A) of the Code in effect on
the Termination Date) through the Six Month Date and paid or provided during the period of 30 consecutive days beginning on the first business day after the Six Month Date (that period of 30 consecutive days, the “Seventh Month after the
Termination Date”), except that if Executive dies before the Six Month Date, the payments, benefits, or reimbursements will be accumulated only through the date of Executive’s death and thereafter paid or provided not later than 30 days
after the date of death. 
 13.2 Earlier Payment if Not a Specified Employee. If Executive is not a “specified
employee” for purposes of Section 409A, as determined under DDR’s policy for determining specified employees on the Termination Date, any lump sum payment to be made by DDR to Executive pursuant to any one or more of Sections
7.2(c), 7.4(c) and 7.5(c) will be made by DDR to Executive during the 30-day period that begins exactly 60 days after the Termination Date rather than during the Seventh Month after the Termination Date.

 13.3 Additional Limitations on Reimbursements and In-Kind Benefits. The reimbursement of expenses or in-kind benefits
provided under Section 7 or under any other section of this Agreement that are taxable benefits (and that are not disability pay or death benefit plans within the meaning of Section 409A of the Code) are intended to comply,
to the maximum extent possible, with the exception to Section 409A set forth in Section 1.409A-1(b)(9)(v) of the Treasury Regulations. To the extent that any reimbursement of expenses or in-kind benefits provided under
Section 7 or under any other section of this Agreement either do not qualify for that exception, or are provided beyond the applicable time periods set forth in Section 1.409A-1(b)(9)(v) of the Treasury Regulations, then they
will be subject to the following additional rules: (i) any reimbursement of eligible expenses will be paid within 30 days following Executive’s written request for reimbursement; provided, that Executive provides written notice no
later than 60 days before the last day of the calendar year following the calendar year in which the expense was incurred so that DDR can make the reimbursement within the time periods required by Section 409A; (ii) the amount of expenses
eligible for reimbursement, or in-kind benefits provided, during any calendar year will not affect the amount of expenses eligible for reimbursement, or in-kind benefits to be provided, during any other calendar year; and (iii) the right to
reimbursement or in-kind benefits will not be subject to liquidation or exchange for any other benefit. 
 13.4 Compliance
Generally. Each payment or reimbursement and the provision of each benefit under this Agreement shall be considered a separate payment and not one of a series of payments 

  
 11 

 
for purposes of Section 409A. DDR and Executive intend that the payments and benefits provided under this Agreement will either be exempt from the application of, or comply with, the
requirements of Section 409A. This Agreement is to be construed, administered, and governed in a manner that effects that intent and DDR will not take any action that is inconsistent with that intent. Without limiting the foregoing, the
payments and benefits provided under this Agreement may not be deferred, accelerated, extended, paid out, or modified in a manner that would result in the imposition of an additional tax under Section 409A upon Executive. 

13.5 Termination of Employment to Constitute a Separation from Service. The parties intend that the phrase “termination of
employment” and words and phrases of similar import mean a “separation from service” with DDR within the meaning of Section 409A. Executive and DDR will take all steps necessary (including taking into account this
Section 13.5 when considering any further agreement regarding provision of services by Executive to DDR after the Termination Date) to ensure that (a) any termination of employment under this Agreement constitutes a
“separation from service” within the meaning of Section 409A, and (b) the Termination Date is the date on which Executive experiences a “separation from service” within the meaning of Section 409A. 

14. Indemnification. DDR will indemnify Executive, to the full extent permitted or authorized by the Ohio
General Corporation Law as it may from time to time be amended, if Executive is made or threatened to be made a party to any threatened, pending, or completed action, suit, or proceeding, whether civil, criminal, administrative, or investigative, by
reason of the fact that Executive is or was a director, officer, or employee of DDR and/or of any Subsidiary, or is or was serving at the request of DDR and/or of any Subsidiary as a director, trustee, officer, or employee of a corporation,
partnership, joint venture, trust, or other enterprise. The indemnification provided by this Section 14 will not be deemed exclusive of any other rights to which Executive may be entitled under the articles of incorporation or the
regulations of DDR and/or of any Subsidiary, or any agreement, vote of shareholders or disinterested directors, or otherwise, both as to action in Executive’s official capacity and as to action in another capacity while holding such office, and
will continue as to Executive after Executive has ceased to be a director, trustee, officer, or employee and will inure to the benefit of Executive’s heirs, executors, and administrators. In particular, Executive will continue to be entitled to
the full benefit of the indemnification agreement dated April 12, 2011 between Executive and DDR (the “Indemnification Agreement”) for so long as that Indemnification Agreement remains in effect according to its terms. In the event of
any conflict or inconsistency between the provisions of this Section 14 and the provisions of the Indemnification Agreement, the provisions of the Indemnification Agreement shall control. 

15. Certain Expenses. This Section 15 will apply only to expenses that (a) are otherwise described
in one or more of its subsections and (b) are incurred at any time from the Effective Date through the fifth anniversary of Executive’s death. 
 15.1 Reimbursement of Certain Expenses. DDR will pay, as incurred, all expenses, including the reasonable fees of counsel engaged by Executive, of Executive in (a) prosecuting any action to
compel DDR to comply with the terms of this Agreement upon receipt from Executive of an undertaking to repay DDR for such expenses if it is ultimately determined by a court of competent jurisdiction that Executive had no reasonable grounds for
bringing such action or (b) defending any action brought by a party other than Executive or Executive’s personal representative to have this Agreement declared invalid or unenforceable. 

  
 12 

 15.2 Advancement of Certain Expenses. Expenses (including the reasonable fees of
counsel engaged by Executive) incurred by Executive in defending any action, suit, or proceeding commenced or threatened against Executive for any action or failure to act as an employee or officer of DDR and/or of any Subsidiary will be paid by
DDR, as they are incurred, in advance of final disposition of the action, suit, or proceeding upon receipt of an undertaking by or on behalf of Executive in which Executive agrees to reasonably cooperate with DDR and/or the Subsidiary, as the case
may be, concerning the action, suit, or proceeding, and if the action, suit, or proceeding is commenced or threatened against Executive for any action or failure to act as an officer or employee, to repay the amount if it is ultimately determined
that Executive is not entitled to be indemnified. The obligation of DDR to advance expenses provided for in this Section 15.2 will not be deemed exclusive of any other rights to which Executive may be entitled under the articles
of incorporation or the regulations of DDR or of any Subsidiary, or any agreement, vote of shareholders or disinterested directors, or otherwise. 
 16. Survival of Obligations. Except as is otherwise expressly provided in this Agreement, the respective obligations of DDR and Executive under this Agreement will survive any
termination of Executive’s employment under this Agreement. 
 17. Notices. Notices and all other
communications provided for in this Agreement must be in writing and will be deemed to have been duly given upon receipt (or rejection) when delivered in person or by overnight delivery (to the CEO of DDR in the case of notices to DDR and to
Executive in the case of notices to Executive) or mailed by United States registered mail, return receipt requested, postage prepaid, and addressed, if to DDR, to its principal place of business, attention: CEO, and, if to Executive, to
Executive’s home address last shown on the records of DDR, or to such other address or addresses as either party may furnish to the other in accordance with this Section 17. 

18. Entire Agreement, Certain Prior Arrangements. Except as otherwise set forth below in this Section 18, this
Agreement supersedes in their entirety all prior employment and change in control agreements between the parties, if any, and all understandings between them, if any, with respect to the subject matter of this Agreement, including, without
limitation, the Employment Agreement, dated April 12, 2011, by and between DDR and Executive. As provided in Section 14, Executive will continue to be entitled to the full benefit of the Indemnification Agreement for so long
as it remains in effect according to its terms. 
 19. Mandatory Arbitration Before a Change in Control.
Section 19.1 will apply if and only if either party notifies the other, in writing, that it is demanding resolution of a then-current controversy or claim by arbitration and the notice is provided by the notifying party to the
other party before any Change in Control has occurred. Nothing in this Section 19 will limit the right of DDR to seek and obtain injunctive relief in a court of equity for any breach or threatened breach by Executive of any of
Executive’s covenants contained in Section 12 above. 
 19.1 Scope of Arbitration. If this
Section 19.1 applies, any controversy or claim arising out of or relating to this Agreement or any breach of this Agreement will be settled by binding arbitration to be held before three arbitrators and conducted in accordance
with the Employment Arbitration Rules and Mediation Procedures of the American Arbitration Association in the City of Cleveland, Ohio. The decision of the arbitrators will be final and binding on both parties and judgment on any award rendered by
the arbitrators may be entered in any court of competent jurisdiction. Costs and expenses of any such arbitration will be borne by the parties as may be directed by the arbitrators taking into account the extent to which the positions taken by each
of 

  
 13 

 
the parties are reasonable. The arbitrators will have the power to issue mandatory orders and restraining orders in connection with any such arbitration. 

19.2 Other Disputes. If Section 19.1 does not apply to any claim or controversy between the parties, the
parties may nevertheless, but need not, mutually agree to submit any controversy or claim to arbitration as though Section 19.1 did apply. Failing any such mutual agreement, either party may bring proceedings against the other
with respect to any claim or controversy in any court of competent jurisdiction that satisfies the venue requirements set forth in Section 20.8. Nothing in this Section 19.2 imposes upon either party any
obligation to discuss possible arbitration of any claim or controversy to which Section 19.1 does not apply before bringing any court proceedings with respect to that claim or controversy. 

20. Miscellaneous. 
 20.1 No Conflict. Executive represents and warrants that Executive is not a party to any agreement, contract, or understanding, whether employment or otherwise, that would restrict or prohibit
Executive from undertaking or performing employment in accordance with the terms and conditions of this Agreement. 
 20.2
Assistance. During the term of this Agreement and thereafter, Executive will provide reasonable assistance to DDR in litigation and regulatory matters that relate to events that occurred during Executive’s period of employment with DDR
and its predecessors, and will provide reasonable assistance to DDR with matters relating to its corporate history from the period of Executive’s employment with it or its predecessors. Executive will be entitled to reimbursement of reasonable
out-of-pocket travel or related costs and expenses relating to any such cooperation or assistance that occurs following the Termination Date. 
 20.3 Severability. The provisions of this Agreement are severable and if any one or more provision is determined to be illegal or otherwise unenforceable, in whole or in part, the remaining
provisions and any partially unenforceable provision to the extent enforceable in any jurisdiction nevertheless will be binding and enforceable. 
 20.4 Benefit of Agreement. The rights and obligations of DDR under this Agreement will inure to the benefit of, and will be binding on, DDR and its successors and assigns, and the rights and
obligations (other than obligations to perform services) of Executive under this Agreement will inure to the benefit of, and will be binding upon, Executive and Executive’s heirs, personal representatives, and assigns. 

20.5 No Waiver. The failure of either party to enforce any provision or provisions of this Agreement will not in any way be
construed as a waiver of any such provision or provisions as to any future violations thereof, nor prevent that party from later enforcing each and every other provision of this Agreement. The rights granted the parties in this Agreement are
cumulative and the waiver of any single remedy will not constitute a waiver of that party’s right to assert all other legal remedies available to it under the circumstances. 

20.6 Modification. This Agreement may not be modified or terminated orally. No modification or termination will be valid unless in
writing and signed by the party against which the modification or termination is sought to be enforced. 

  
 14 

 20.7 Merger or Transfer of Assets of DDR. During the Contract Period
while Executive is employed by DDR, DDR will not consolidate with or merge into any other corporation, or transfer all or substantially all of its assets to another corporation, unless such other corporation assumes this Agreement in a signed
writing and delivers a copy thereof to Executive, which signed writing may consist of the merger or sale agreement, or similar document. Upon any such assumption, the successor corporation will become obligated to perform the obligations of DDR
under this Agreement, and the term “DDR,” as used in this Agreement, will be deemed to refer to that successor corporation, and the term “the Board” as used in this Agreement will be deemed to refer to the board of directors of
that successor corporation. 
 20.8 Governing Law and Venue. The provisions of this Agreement will be governed by and
construed in accordance with the laws of the State of Ohio applicable to contracts made in and to be performed exclusively within that State, notwithstanding any conflict of law provision to the contrary. Subject to the mandatory arbitration
provisions of Section 19, the parties consent to venue and personal jurisdiction over them in the courts of the State of Ohio and federal courts sitting in Cleveland, Ohio, for purposes of construing and enforcing this Agreement.

 20.9 Termination of Status as Director or Officer. Notwithstanding anything in this Agreement to the contrary, unless
otherwise agreed to by DDR and Executive prior to the Termination Date, Executive shall be deemed to have automatically resigned from all directorships and offices with DDR and its Subsidiaries, and their affiliates (including joint ventures), as of
the Termination Date. 
 21. Definitions. 
 21.1 Reserved. 
 21.2 Reserved. 

21.3 Cause. The term “Cause” has the meaning set forth in Section 6.2. 

21.4 Change in Control. The term “Change in Control” means the occurrence, during the Contract Period while Executive is
employed by DDR, of any of the following: 
 (a) consummation of a consolidation or merger in which DDR is not the surviving
corporation, the sale of substantially all of the assets of DDR, or the liquidation or dissolution of DDR; 
 (b) any person or
other entity (other than DDR or a Subsidiary or any DDR employee benefit plan (including any trustee of any such plan acting in its capacity as trustee)) purchases any Shares (or securities convertible into Shares) pursuant to a tender or exchange
offer without the prior consent of the Board, or becomes the beneficial owner of securities of DDR representing 30% or more of the voting power of DDR’s outstanding securities without the prior consent of the Board of Directors of DDR (the
“Board”); or 
 (c) during any two-year period, individuals who at the beginning of such period constitute the entire
Board cease to constitute a majority of the Board; provided, that any person becoming a director of DDR during such two-year period whose election, or 

  
 15 

 
nomination for election by DDR’s shareholders, was approved by a vote of at least two-thirds of the directors who at the beginning of such period constituted the entire Board (either by a
specific vote or by approval of DDR’s proxy statement in which such person is named as a nominee of DDR for director), but excluding for this purpose any person whose initial assumption of office as a director of DDR occurs as a result of
either an actual or threatened election contest with respect to the election or removal of directors of DDR or other actual or threatened solicitation of proxies or consents by or on behalf of an individual, corporation, partnership, group,
associate or other entity or person other than the Board, shall be, for purposes of this Section 21.4(c), considered as though such person was a member of the Board at the beginning of such period. 

21.5 Committee. The term “Committee” means Executive Compensation Committee of the Board or any other committee or
subcommittee authorized by the Board to discharge the Board’s responsibilities relating to the compensation of DDR’s executives and directors. 
 21.6 Reserved. 
 21.7 Reserved. 

21.8 Good Reason. The term “Good Reason” has the meaning set forth in Section 6.3. 

21.9 Internal Revenue Code. The term “Internal Revenue Code” means the Internal Revenue Code of 1986, as amended.

 21.10 Reserved. 
 21.11 Section. References in this Agreement to one or more “Sections” are to sections of this Agreement, except for references to Section 409A, which are references to that section
of the Internal Revenue Code. 
 21.12 Section 409A. The term “Section 409A” means Section 409A
of the Internal Revenue Code. References in this Agreement to Section 409A are intended to include any proposed, temporary, or final regulations, or any other guidance, promulgated with respect to Section 409A by the U.S. Department of
Treasury or the Internal Revenue Service. 
 21.13 Shares. The term “Shares” means the Common Shares, par value
$0.10 per share, of DDR. 
 21.14 Subsidiary. The term “Subsidiary” means any corporation, partnership, or
other entity a majority of the voting control of which is directly or indirectly owned or controlled by DDR. 
 21.15
Termination Date. The term “Termination Date” means the date on which Executive’s employment with DDR and its Subsidiaries terminates. 
 21.16 Triggering Event. A “Triggering Event” for the purpose of this Agreement will be deemed to have occurred if, during the Contract Period while Executive is employed by DDR:

 (a) Within two years after the date on which a Change in Control occurs, DDR terminates the employment of Executive, other
than in the case of a termination for 

  
 16 

 
Cause, a termination by DDR pursuant to Section 6.1 following Executive’s disability, or a termination based on death; 

(b) Within two years after the date on which a Change in Control occurs, DDR reduces Executive’s title, responsibilities, power or
authority in comparison with Executive’s title, responsibilities, power or authority at the time of the Change in Control and Executive thereafter terminates Executive’s employment with DDR within such two-year period; 

(c) Within two years after the date on which a Change in Control occurs, DDR assigns Executive duties which are inconsistent with the
duties assigned to Executive on the date on which the Change in Control occurred and which duties DDR persists in assigning to Executive despite the prior written objection of Executive and Executive thereafter terminates Executive’s employment
with DDR within such two-year period; 
 (d) Within two years after the date on which a Change in Control occurs, DDR
(i) reduces Executive’s base compensation, Executive’s incentive opportunity bonus percentages of salary, Executive’s health and dental insurance coverage and benefits (including any such benefits provided to Executive’s
eligible dependents), Executive’s pension, retirement, or profit-sharing benefits or any benefits provided by any of DDR’s equity-based award plans, or any substitute therefor, unless in any case such reduction applies generally to all
employees of DDR, (ii) establishes criteria and factors to be achieved for the payment of bonus compensation that are substantially different than the criteria and factors established for other similar executive officers of DDR,
(iii) fails to pay Executive any bonus compensation to which Executive is entitled through the achievement of the criteria and factors established for the payment of such bonus, or (iv) excludes Executive from any plan, program, or
arrangement in which the other executive officers of DDR are included, and Executive thereafter terminates Executive’s employment with DDR within such two-year period; or 
 (e) Within two years after the date on which a Change in Control occurs, DDR requires Executive to be based at or generally work from any location more than fifty miles from the geographical center of
Cleveland, Ohio and Executive thereafter terminates Executive’s employment with DDR within such two-year period. 
 21.17
Reserved. 
 [THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 17 

 IN WITNESS WHEREOF, DDR and Executive have executed this Agreement, DDR by
its duly authorized Chief Executive Officer, on the date first written above. 
  

			
	DDR CORP.
		
	 By:
	 	/s/ Daniel B. Hurwitz            
		 	 Daniel B. Hurwitz, President & Chief
 Executive Officer

	
	/s/ Christa A. Vesy            
	Christa A. Vesy

  
 18 

 EXHIBIT A 

ANNUAL CASH BONUS OPPORTUNITY 
 AS A PERCENTAGE OF YEAR-END BASE SALARY 
  

									
	 Threshold
	  	Target	 	 	Maximum	 
	 20%
	  	 	40	% 	 	 	80	% 

 PERFORMANCE METRICS AND RELATIVE WEIGHTING 

FOR 2012 ANNUAL CASH BONUS OPPORTUNITY 
  

					
	 Performance Metrics
	  	Relative Weighting	 
	 Same Store EBITDA
	  	 	55	% 
	 Relative Total Shareholder Return
	  	 	10	% 
	 Strategic Objectives
	  	 	20	% 
	 CFO Assessment
	  	 	15	% 

 ANNUAL EQUITY BONUS OPPORTUNITY 

AS A PERCENTAGE OF YEAR END BASE SALARY PLUS AMOUNTS EARNED UNDER 

THE ANNUAL CASH BONUS 
  

									
	 Threshold
	  	Target	 	 	Maximum	 
	 12.5%
	  	 	25	% 	 	 	50	%First Right to Negotiate and Amendment Agreement

 EXHIBIT 10.1 
 FIRST RIGHT TO NEGOTIATE AND AMENDMENT AGREEMENT 
 This
First Right to Negotiate and Amendment Agreement (this “Agreement”) is made effective this
2nd day of March, 2012 (“Amendment Effective
Date”) by and between Agenus Inc., a Delaware Corporation (“Agenus”), Antigenics Inc., a Massachusetts corporation and wholly owned subsidiary of Agenus (“Antigenics MA”), and GlaxoSmithKline Biologicals
SA, a Belgian company (“GSK”) (each singularly a “Party” and collectively the “Parties”). 
 WHEREAS, Antigenics MA and GSK were parties to that certain License, Development, and Supply Agreement entered into effective September 11, 1992 between Cambridge Biotech Corporation (predecessor to
Antigenics MA) and SmithKline Beecham p.l.c. (predecessor to GlaxoSmithKline plc an Affiliate of GSK) (as amended, the “1992 Agreement”); and 
 WHEREAS Antigenics MA and GSK terminated and superseded the 1992 Agreement with that certain License Agreement entered into effective July 6, 2006 between the Parties (as amended by the Letter
defined below, the “License Agreement”) and that certain Manufacturing Technology Transfer and Supply Agreement entered into effective July 6, 2006 between the Parties (the “2006 Supply Agreement”); and

 WHEREAS, the Parties entered into that certain Binding Letter of Intent dated July 20, 2007 (the
“Letter”) to, among other things, accelerate GSK’s manufacturing rights for QS-21 under the 2006 Supply Agreement; and 
 WHEREAS, GSK and Antigenics MA superseded and amended and restated the 2006 Supply Agreement with the Amended and Restated Manufacturing Technology Transfer Agreement dated January 16, 2009 (the
“Amended Manufacturing Agreement”); and 
 WHEREAS, the Parties desire to grant GSK a first right to negotiate
for the purchase of Agenus, and to further amend the License Agreement and the Amended Manufacturing Agreement to clarify certain provisions and grant GSK additional rights thereunder. 

NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties do hereby agree as follows: 

1. First Right to Negotiate 
 1.1 In consideration of the first right to negotiate (the “FRTN”) granted by Agenus to GSK in this Section 1 as well as the other rights and licenses provided for in this Agreement,
GSK hereby agrees to pay the consideration set forth in Section 4 of this Agreement. 

  
 [**] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 1.2 If the Agenus Board of Directors (i) determines to initiate a
process or to undertake discussions with a third party other than an Affiliate of Agenus (a “Third Party Process”) for either: (a) a negotiated transaction or series of transactions that would result in a Change of Control of
Agenus, or (b) a sale, assignment, or other disposition of the License Agreement and Amended Manufacturing Agreement by Antigenics MA (other than to an Affiliate of Antigenics MA), or (c) a sale or other disposition of all or substantially
all of the Antigenics MA assets relating to QS-21, or (ii) a third party commences an unsolicited tender offer seeking to effect a Change of Control of Agenus unrelated to a Third Party Process (an “Unsolicited Tender Offer”),
in each case of the foregoing Agenus shall comply with this Section 1. For the avoidance of doubt and notwithstanding the foregoing, this Section 1 shall not apply with respect to any sale, assignment or other disposition of that certain
[**], [**] or any rights of Antigenics MA of Agenus with respect thereto or thereunder, where such sale, assignment or other disposition does not occur as part of a broader transaction for which a notice requirement would be triggered pursuant to
Section 1.2 (i) (a), (b) or (c) or 1.2 (ii) above. For purposes hereof, “Change of Control” shall mean, with respect to a Party, any of the following events: (x) any person (or group of persons acting
in concert) becomes the beneficial owner, directly or indirectly, of more than fifty percent (50%) of the total voting power of the capital stock then outstanding of such Party normally entitled to vote in elections of directors; (y) such
Party consolidates with or merges into another corporation or entity, or any corporation or entity consolidates with or merges into such Party, in either event pursuant to a transaction in which more than fifty percent (50%) of the total voting
power of the capital stock outstanding of the surviving entity entitled to vote in elections of directors is not held by persons holding at least fifty percent (50%) of the outstanding shares of such Party preceding such consolidation or
merger; or (z) such Party conveys, transfers or leases all or substantially all of its assets to any person. 
 1.3 In the event that the Agenus Board of Directors determines to commence a Third Party Process, it shall provide GSK with written notice of such determination, such notice shall state whether the Third
Party Process is under Section 1.2 (i) (a), (b) or (c). GSK shall have [**] days from receipt of such notice from Agenus (the “[**] Day Option Period”) to inform Agenus in writing whether it in good faith desires to
negotiate with Agenus the terms of a transaction of the type described in the notice. If GSK does so affirmatively inform Agenus, then, during the ensuing [**]-day period from the date of GSK’s written notice (the “[**] Day Negotiation
Period”), Agenus and GSK in good faith will seek to negotiate the terms of a definitive agreement for that transaction. 
 1.4 If a third party commences an Unsolicited Tender Offer, Agenus shall provide GSK with a written notice of the Unsolicited Tender Offer. Prior to the expiration of [**] days after delivery of such
notice by Agenus (the “[**] Day Option Period”, and together with the [**] Day Option Period applicable in Section 1.3, hereinafter referred to as an “Option Period”), GSK shall inform Agenus in writing whether
it desires to negotiate with Agenus the terms of a transaction as described in the 

  
 [**] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
Unsolicited Tender Offer. If GSK does so affirmatively inform Agenus, then, during the ensuing [**]-day period (the “[**]-Day Negotiation Period” and, together with the [**]-Day
Negotiation Period, hereinafter referred to as a “Negotiation Period”), Agenus and GSK in good faith will seek to negotiate the terms of a definitive agreement for that transaction. 

1.5 GSK shall promptly notify Agenus in writing if it determines at any time during the applicable Option Period or
Negotiation Period that it does not wish, or it no longer wishes, to negotiate a transaction, and upon Agenus’ receipt of such notice, the applicable Option Period or Negotiation Period shall immediately terminate. 

During the pendency of any applicable Option Period and/or Negotiation Period, Agenus shall not enter into any definitive
agreement which would preclude Agenus from negotiating and/or executing a definitive agreement with GSK with respect to a transaction of the type described in the relevant notice or Unsolicited Tender Offer, as applicable. 

1.6 If GSK does not affirmatively elect to proceed to a Negotiation Period during any applicable Option Period, or if GSK
and Agenus do not enter into a definitive agreement for a Transaction during any applicable Negotiation Period, Agenus may enter into a definitive agreement for and/or consummate a Transaction with any third party at any time during the [**] months
following the expiration or earlier termination of the applicable Option Period or Negotiation Period; provided that, to the extent applicable, Agenus will not enter into such a definitive agreement for and/or consummate such a Transaction on terms
in the aggregate materially less favorable to Agenus and its stockholders (as determined by the Agenus Board of Directors, in its reasonable discretion) than the terms last offered to Agenus by GSK in a binding written proposal during the applicable
Negotiation Period. 
 1.7 If a transaction as described in Section 1.2 (i) (a), (b) or
(c) or 1.2 (ii) above is not concluded with a third party during such [**]-month period, GSK’s FRTN pursuant to this Section 1 will apply again to any Third Party Process or Unsolicited Tender Offer prior to the termination of
the FRTN pursuant to Section 1.10. 
 1.8 The FRTN will not be transferable or assignable by GSK except to a
successor to the business to which this Agreement, the License Agreement, and the Amended Manufacturing Agreement relate, whether by merger or acquisition of all of its outstanding stock or otherwise. 

1.9 Any confidential information of Agenus that is provided to GSK during the course of negotiations pursuant to exercise
of the FRTN by GSK will be held in confidence pursuant to the terms of Article 9 of the Amended Manufacturing Agreement. 

  
 [**] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 1.10 This Section 1 shall terminate, and the FRTN shall expire and be
of no further force and effect, upon the fifth (5th) anniversary of this Agreement. 
 2. License Agreement Amendments.
Antigenics MA and GSK acknowledge and agree that the License Agreement is hereby amended as follows: 
 2.0 All references in
this Agreement to the Supply Agreement are now to be understood to mean the Amended Manufacturing Agreement. 

2.1 QS-21 Vaccines. The following definition is hereby added to the License Agreement: 

“QS-21 Vaccine” means: (i) with respect to any Vaccine product covered by a Valid Claim of the Patent Rights, any
Licensed Vaccine, whether prophylactic or therapeutic, and (ii) with respect to any Vaccine product not covered by a Valid Claim of the Patent Rights, any prophylactic and/or therapeutic Vaccine product that elicits an immune response to
antigen(s) directed to any indications whether such indications are listed or not in the License Agreement, provided however that Licensed Vaccine and QS-21 Vaccine specifically excludes any and all [**]. As used herein,
“[**]” shall mean the [**]. As used herein “[**]” shall mean an [**]. 
 2.2 Rights in
[**]. Section 1.10 of the License Agreement is hereby amended to include QS-21 Vaccines for use in [**] as an “Exclusive Vaccine” and Exhibit C of the License Agreement is hereby amended to include the [**], in each case
subject to the exclusion for [**]. 
 2.3 Licensed Know-how. The terms “Licensed Vaccines” in
Section 1.17 of the License Agreement are hereby replaced with the terms “Licensed Vaccines or QS-21 Vaccines”. 
 2.4 Licensed Technology Rights. Section 2.1(e) of the License Agreement is hereby deleted in its entirety and replaced with the following: 

(e) a non-exclusive, royalty-free license, with the right to sublicense solely as set forth in Section 2.2 below, under the Licensed
Technology to use QS-21 to develop, make, have made, use, sell, offer for sale, keep and import QS-21 Vaccines within the Territory. 

  
 [**] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 2.5 Clarification to Section 2.1. The last paragraph of
Section 2.1 of the License Agreement is hereby deleted in its entirety and replaced with the following: 
 For the
avoidance of doubt, and subject to the foregoing provisions of this Section 2.1 and the provisions of Section 2.2 and the Supply Agreement, nothing in this Agreement shall restrict GSK’s ability to: (i) exploit its own technology
or to carry out research within or outside the Licensed Indications, and/or (ii) collaborate or subcontract with Third Parties and transfer QS-21 to such Third Party collaborators or subcontractors in furtherance of the licenses granted to GSK
pursuant to this Section 2.1, provided that Agenus’ rights under this Agreement and the Supply Agreement would not be compromised and provided further that nothing in this Agreement shall be construed as Antigenics MA granting GSK any
affirmative right to use the Licensed Technology and the Licensed Patent Rights other than as expressly provided in this Section 2.1. In addition, nothing in this Agreement shall grant GSK any right to manufacture (or have made) QS-21, it
being the understanding of the Parties that the provision of such a manufacturing right is the subject of the Supply Agreement.
 2.6 Sublicensing Rights. The first sentence of Section 2.2 and Section 2.2 (a) of the License Agreement are hereby deleted in their entirety and replaced with the following:

 2.2 Sublicensing. GSK shall have the right to grant sublicenses to (a) Affiliates and/or (b) Third
Parties for use in any QS-21 Vaccines, to the license rights granted to GSK in Section 2.1 above, subject to the following terms and conditions: 
 (a) GSK may grant sublicenses to Affiliates and/or Third Parties (i) for Exclusive Vaccines without Antigenics MA’s prior written consent provided that the Sublicensee will practice the Licensed
Patent Rights and Licensed Technology only to the extent granted to GSK under this Agreement and GSK and the Sublicensee will comply with the remaining provisions of this Section 2.2; and (ii) for all other QS-21 Vaccines as part of a
license or sublicense to GSK’s proprietary adjuvant systems, with Antigenics MA’s consent (such consent not to be unreasonably withheld), provided that the Sublicensee will practice the Licensed

  
 [**] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
Patent Rights and Licensed Technology only to the extent granted to GSK under this Agreement and GSK and the Sublicensee will comply with the remaining provisions of this Section 2.2, and
provided further that Antigenics MA receives Sublicense Revenues in accordance with the terms of the License Agreement for at least as long as Antigenics MA has the right to receive payments under the Amended Manufacturing Agreement. For the
avoidance of doubt, it shall not be deemed unreasonable for Antigenics MA to withhold consent under Section 2.1(a)(ii) in the event the Third Party Sublicensee is seeking to develop and commercialize their own products containing QS-21 outside
of a research, development and/or commercial collaboration or cross-license arrangement with GSK and Antigenics MA does not receive Sublicense Revenues in accordance with the foregoing. For purpose of clarification, GSK shall have no obligation to
seek prior consent or notify and/or provide Antigenics MA a copy of such a sublicense agreement in the case where GSK grants a sublicense to a Third Party for research purpose only and does not get any Sublicense Revenue from that Third Party. The
right of Antigenics MA to receive Sublicense Revenues as set forth in this paragraph shall survive any expiration or termination of this Agreement. 
 In addition, for purposes of clarity, the title of Section 10.4 of the License Agreement is hereby amended to read: “Termination or Continuation for Bankruptcy of Antigenics MA; Effects of
Termination of this Agreement”, and Section 10.4(c) of the License Agreement is hereby amended by adding reference to Section 2.2 to the second sentence. 

For the avoidance of doubt, upon expiration of the License Agreement any existing Sublicensee or further Sublicensee shall
continue to be a direct Sublicensee(s) of GSK and not become a direct licensee of Antigenics MA. 
 2.7
Exclusion. Notwithstanding the foregoing or any other provisions of this Agreement and for the avoidance of doubt, GSK shall have no rights under the License Agreement with respect to [**]. 

2.8 Public Announcements. Section 12.6 of the License Agreement is hereby amended to add the following
provision: 
 In addition to and notwithstanding any other provision of

  
 [**] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
this Agreement or the Amended Manufacturing Agreement, the Parties acknowledge and agree that at Antigenics MA’s election, GSK and its Sublicensees or contractors, as applicable, shall state
that Agenus’/Antigenics MA’s QS-21 is contained in any QS-21 Vaccine mentioned in any press release regarding positive Phase 3 data, submission or acceptance of application for regulatory approval, receipt of regulatory approval, and/or
first commercial launch of such vaccine. GSK shall provide Antigenics MA with reasonable advance notice of any such press release to give Antigenics MA reasonable time to make any such election and approve any language relating thereto. For purpose
of clarification, GSK shall be entitled, without obligation, to state that Agenus’/Antigenics MA’s QS-21 is contained in any QS-21 Vaccine mentioned in any press release regarding Phase 3 data other than a press release regarding positive
Phase 3 data. 
 3. Amended Manufacturing Agreements. Antigenics MA and GSK acknowledge and agree that the Amended
Manufacturing Agreement is hereby amended as follows: 
 3.1 QS-21 Vaccines. Section 1.31 of the
Amended Manufacturing Agreement (QS-21 Vaccine(s)) is hereby deleted in its entirety and replaced with the definition set forth in Section 2.1 of this Agreement. 

3.2 Scope of Manufacturing License. Section 2.5(a) of the Amended Manufacturing Agreement is hereby deleted in
its entirety and replaced with the following: 
 (a) Subject to the terms and conditions of this Agreement
(including without limitation, the provisions of Article 4 below and the retained rights of Antigenics MA set forth in Section 2.5(b) below), Antigenics MA hereby grants to GSK: (A) a world-wide, non-exclusive, right and license
(with the right to grant sublicenses to its Affiliates and Sublicensees as defined in the License Agreement, subject to the provisions of Section 2.5(c) below) to the Manufacturing Technology for the sole purpose of Manufacturing QS-21:
(i) to supply Antigenics MA (and its Affiliates and QS-21 licensees and customers) in accordance with this Agreement, and (ii) to develop, make, have made, use, sell, offer for sale and import QS-21 Vaccines (other than QS-21 Vaccines for
use in the [**]), and (B) a world-wide, exclusive, right and license (with the right to grant sublicenses to its Affiliates and Sublicensees as defined in the License Agreement, subject to the

  
 [**] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
provisions of Section 2.5(c) below) to the Manufacturing Technology for the sole purpose of Manufacturing QS-21 to develop, make, have made, use, sell, offer for sale and import QS-21
Vaccines for use in the [**]. As used in this Agreement, “[**]” means the [**]. 
 3.3 Exclusion.
Notwithstanding the foregoing or any other provisions of this Agreement and for the avoidance of doubt, GSK shall have no rights under the Amended Manufacturing Agreement with respect to [**]. 

3.4 Section 5.3 of the Amended Manufacturing Agreement is hereby amended by adding the following provision

 In addition to and notwithstanding the foregoing, in no event shall the foregoing Manufacturing Technology Transfer Royalty
obligation apply with respect to QS-21 Vaccines in the [**] for less than seven (7) years after the First Commercial Sale of the first prophylactic or first therapeutic QS-21 Vaccine in the [**]. 

4. Consideration. In consideration for the rights and licenses granted to GSK by Antigenics MA hereunder, GSK has agreed to amend
Section 5.3 of the Amended Manufacturing Agreement as set forth above. Furthermore and in consideration for the FRTN granted to GSK by Agenus under this Agreement, GSK shall pay Agenus a non-refundable, one-time payment in the amount of US$
9,000,000 within ten (10) Business Days of the Amendment Effective Date, of which U.S. $2,500,000 shall be creditable against future Manufacturing Technology Transfer Royalty payments otherwise owing to Antigenics MA under Section 5.3 of
the Amended Manufacturing Agreement. 
 5. Representations and Warranties. 

5.1 Antigenics Inc. and Agenus Inc. hereby represent and warrant to GSK that: (a) they have the right to enter into
this Agreement and to grant GSK the rights and licenses granted hereunder; and (b) the execution, delivery and performance of this Agreement by them does not (i) conflict with any agreement, instrument or understanding, oral or written, to
which either of them or any of their affiliates is a party and by which they may be bound or (ii) violate any laws of any governmental authority having jurisdiction; and (c) it is not aware of any breach of the License Agreement or the
Amended Manufacturing Agreement by Antigenics Inc. or any of its affiliates. 
 5.2 GSK hereby represents and
warrants to Agenus and Antigenics Inc. that: (a) it has the right to enter into this Agreement and perform its obligations hereunder; and (b) the execution, delivery and performance of this Agreement by it does not (i) conflict

  
 [**] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
with any agreement, instrument or understanding, oral or written, to which it or any of its affiliates is a party and by which they may be bound or (ii) violate any laws of any governmental
authority, and (c) it is not aware of any breach of the License Agreement or the Amended Manufacturing Agreement by GSK or any of its affiliates or sublicensees. 
 6. Release. Antigenics Inc. and Agenus Inc., on the one hand, and GSK on the other hand, each on behalf of themselves and their respective successors and assigns, hereby release one another and
their respective subsidiaries, divisions, parents, affiliates and agents, each of their respective directors, officers, employees, representatives and agents, and each of their respective successors, assigns and other transferees, from any and all
causes of action, claims, counterclaims, defenses, damages and demands whatsoever, in law or in equity known to the releasing party and relating to the subject matter of the License Agreement or Amended Manufacturing Agreement, whether
(a) relating to use of Manufacturing Technology (as such term is defined in the Amended Manufacturing Agreement) and/or Licensed Technology (as such term is defined in the Licensed Agreement), (b) relating to any tort, contract or other
claim arising prior to the Effective Date, or (c) arising or claimed to arise out of any infringement or asserted infringement of any intellectual property owned or controlled by Antigenics Inc., Agenus Inc. and/or their affiliates prior to the
Effective Date, in each case which releasing party ever had, now has or hereafter shall or may have, that can be, could be or could have been asserted by Antigenics Inc., Agenus Inc. and/or their affiliates in any judicial or non-judicial
proceeding. For the avoidance of doubt, the Parties do not hereby release any rights arising out of facts or circumstances unknown to the releasing party. 
 7. Miscellaneous 
 7.1 Any capitalized terms not defined
herein shall have the meanings in the License Agreement or the Amended Manufacturing Agreement, as applicable. 

7.2 The Parties acknowledge and agree that, except as set forth in this Agreement, the License Agreement and Amended
Manufacturing Agreement shall remain unchanged and in full force and effect. 
 7.3 Further Actions. Each
Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

7.4 Severability. If any provision of this Agreement, or part thereof, is found by a proper authority to be
unenforceable, that provision, or part thereof, shall be stricken and the remainder of this Agreement will continue in full force and effect; provided, however, that the Parties shall renegotiate an acceptable replacement provision so as to
accomplish, as nearly as possible, the original intent of the Parties. 
 7.5 Applicable Law; Governing
Language. This Agreement shall be governed 

  
 [**] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
and construed in accordance with the laws of the State of Delaware, without regard to conflicts of laws principles. This Agreement has been prepared in the English language and the English
language shall control its interpretation. All consents, notices, reports and other written documents to be delivered or provided by a Party under this Agreement shall be in the English language, and in the event of any conflict between the
provisions of any document and the English language translation thereof, the terms of the English language translation shall control. 
 7.6 Notices and Deliveries. Any notice or other communication required or permitted hereunder shall be in accordance with the License Agreement, provided that notices to Agenus and/or Antigenics MA
shall be to the attention of the Chief Financial Officer or Agenus Inc with a copy to Agenus Inc. Legal Department. 
 7.7 Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
instrument. If any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the Party executing (or on whose behalf such signature is
executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof. 
 7.8 No Admission. Nothing contained in this Agreement, its execution, or delivery, or the performance of any obligation herein, or the exercise of any right or license herein, shall be construed as
an admission by any party of any wrongdoing, liability, or potential claims, and the Parties recognize that each expressly denies any liability or potential liability 

7.9 Survival in the Event of Bankruptcy. All rights, releases and covenants granted under or pursuant to this
Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under section 101 of the U.S. Bankruptcy Code. The Parties hereby
acknowledge and agree that Novartis shall retain and may fully exercise all of its rights and elections under the U.S Bankruptcy Code. 
 7.10 Headings. Descriptive headings and titles used in this Agreement are inserted for convenience of reference only and do not constitute a part of and shall not be utilized in interpreting this
Agreement. 
 7.11 Relationship of the Parties. This Agreement is not intended by the Parties to
constitute or create a joint venture, pooling arrangement, partnership, or formal business organization of any kind, and the rights and obligations of the Parties shall be only those expressly set forth herein and therein. No Party will have any
right, power or 

  
 [**] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 
authority, nor will they represent themselves as having any authority to assume, create or incur any expense, liability or obligation, express or implied, on behalf of another Party, or otherwise
act as an agent for another Party for any purpose. 
 [The remainder of this page is intentionally left blank.] 

  
 [**] =
Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 

 IN WITNESS WHEREOF, the Parties hereto have caused this First Right to
Negotiate and Amendment Agreement to be signed by their respective corporate officers, duly authorized as of the day and year first above written. 
  

									
	Agenus Inc.	 		 	Antigenics Inc.
					
	By:	 	 /s/ Garo H. Armen
	 		 	By:	 	 /s/ Garo H. Armen

					
	Name:	 	Garo H. Armen, PhD	 		 	Name:	 	Garo H. Armen, PhD
					
	Title:	 	Chairman and CEO	 		 	Title:	 	Chairman and CEO
				
	GlaxoSmithKline Biologicals SA	 		 		 	
					
	By:	 	 /s/ T. Breuer
	 		 	By:	 	 /s/ D. Dubru

					
	Name:	 	T. Breuer	 		 	Name:	 	D. Dubru
					
	Title:	 	SVP of R&D, Director	 		 	Title:	 	VP Finance Operations, Director

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An
unredacted version of this exhibit has been filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]